動脈硬化性疾患治療の新たなストラテジー

出版社： 先端医学社
著者：
発行日： 2005-07-20
分野： 臨床医学：内科  >  内分泌/代謝
ISBN： 4884071956
電子書籍版： 2005-07-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,475 円(税込)

購入する

商品紹介

生活習慣病が比較的軽症でも集積すると動脈硬化発症率が極めて高くなる。この病態をメタボリックシンドロームとよび、わが国でも2005年4月に日本人の診断基準が発表された。一方、内臓脂肪の基礎的研究を通して本シンドロームの発症機序も解明されつつある。今後ますます重要な位置づけがなされていく本シンドロームの疾患概念から臨床応用、研究の最前線までを丁寧に解説。医療従事者必読の書。

目次

  • 動脈硬化性疾患治療の新たなストラテジー

    ―目次―

    Part 1☆動脈硬化性疾患とメタボリックシンドローム
    −メタボリックシンドロームの基礎知識を得る−
    　総論：メタボリックシンドロームの病態を探る
    　1：メタボリックシンドロームの疫学を探る
    　2：メタボリックシンドロームの発症機序を探る
    　3：メタボリックシンドロームの対策を探る

    Part 2☆メタボリックシンドロームにおける脂質代謝異常
    −動脈硬化性疾患の予防における高脂血症治療の根拠を探る−
    　総論：メタボリックシンドロームから脂質代謝異常を探る
    　1：高トリグリセリド血症の動脈硬化への影響を探る
    　2：HDLを介した動脈硬化防御技術開発の展望と限界
    　3：レムナントと動脈硬化性イベントの関連を探る
    　4：small dense LDLの動脈硬化惹起性を探る

    Part 3☆メタボリックシンドロームとPPARの関連性
    　−PPARの機能を探る−
    　総論：メタボリックシンドロームの分子標的としてのPPARsを探る
    　1：PPARαの脂質・糖代謝への影響を探る
    　2：PPARγの糖代謝への影響を探る
    　3：PPARδと脂肪細胞の関連を探る

    Part 4☆PPARαアゴニストとしてのフィブラートの役割
    　−メタボリックシンドロームにおける
    　　フィブラートの有用性を探る−
    　総論：PPARアゴニストとしてのフィブラートの可能性を探る
    　1：脂質代謝異常におけるフィブラートの可能性を探る
    　2：フィブラートによる脂質プロフィールに及ぼす影響を探る
    　3：食後高脂血症に対するフィブラートの影響力を探る
    　4：フィブラートのsmall dense LDLへの影響力を探る
    　5：低HDLコレステロール血症における
    　　　フィブラートの有用性を探る
    　6：フィブラートによるインスリン抵抗性への影響と効果を探る
    　7：フィブラートによる脂肪毒性解除の可能性を探る
    　8：フィブラートの肝臓における作用を探る

    Part 5　☆動脈硬化性疾患の新たな治療指針
    　−メタボリックシンドロームに対する実践的診療に向けて−
    　メタボリックシンドローム診断のためのフローチャート

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 動脈硬化性疾患とメタボリックシンドローム―メタボリックシンドロームの基礎知識を得る―

P.16 掲載の参考文献
1) 動脈硬化性疾患診療ガイドライン2002年版, 日本動脈硬化学会編, 2002
 
2) Reaven GM:Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988 (PMID:3056758)
 
3) Kaplan NM:The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514-1520, 1989 (PMID:2662932)
 
4) DeFronzo RA, Ferrannini E:Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991 (PMID:2044434)
 
5) Fujioka S, Matsuzawa Y, Tokunaga K et al:Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59, 1987 (PMID:3796297)
 
6) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001 (PMID:11368702)
 
7) Hotamisligil GS, Arner P, Caro JF et al:Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995 (PMID:7738205)
 
8) Steinberg HO, Tarshoby M, Monestel R et al:Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1OO:1230-1239, 1997 (PMID:9276741)
 
9) Ouchi N, Kihara S, Arita Y et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999 (PMID:10982546)
 
10) Okamoto Y, Kihara S, Ouchi N et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002 (PMID:12451000)
 
11) Meigs JB, Wilson PW, Nathan DM et al:Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52:2160-2167, 2003 (PMID:12882936)
 
12) Tuomilehto J, Lindstrom J, Eriksson JG et al, Finnish Diabetes Prevention Study Group:Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001 (PMID:11333990)
 
P.22 掲載の参考文献
1) National Cholesterol Education Program:Executive Summary of the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA 285:2486-2497, 2001 (PMID:11368702)
 
2) Modan M, Halkin H, Almogs et al:Hyperinsulinemia. A link between hypertension, obesity, and glucose intolerance. J Clin Invest 75:808-814, 1985 (PMID:3884667)
 
3) Ferrannini E, Buzzigoli G, Bonadonna R et al:Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987 (PMID:3299096)
 
4) 青山真也, 斎藤重幸, 高木覚ほか:高インスリン血症と心血管疾患危険因子との関連. 糖尿病 42:495-502, 1999
 
5) 老松寛, 斎藤重幸, 浦信行ほか:インスリン抵抗性の簡便な臨床評価法に関する検討-本態性高血圧での検討. 糖尿病 43:205-213, 2000
 
6) Meigs JB, D'Agostino RB Jr, Wilson PW et al:Risk variable clustering the insulin resistance syndrome:the Framingham Offspring Study. Diabetes 46:1594-1600, 1997 (PMID:9313755)
 
7) Zavaroni I, Bonora E, Pagliara M et al:Risk Factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320:702-706, 1989 (PMID:2646537)
 
8) Pyorala M, Miettinen H, Laakso M et al:Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men:the 22-year follow-up results of the Helsinki Policemen Study. Circulation 98:398-404, 1998 (PMID:9714089)
 
9) Ruige JB, Assenddelft WJ, Dekker JM et al:Insulin and risk of cardiovascular disease:a meta-analysis. Circulation 97:996-1001, 1998 (PMID:9529268)
 
10) Ford ES, Giles WH, Dietz WH:Prevalence of the metabolic syndrome Among US Adults:Finding Form the Third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002 (PMID:11790215)
 
11) 竹内宏ほか:NCEP-ATP III, Metabolic Syndromeとインスリン抵抗性の関連, 男女別検討-端野・壮瞥研究-. 第7回心血管内分泌代謝学会 Program and Abstracts, 2003, p104
 
12) Lakka HM, Laaksonen DE, Lakka TA et al:The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002 (PMID:12460094)
 
P.29 掲載の参考文献
1) Matsuzawa Y, Funahashi T, Nakamura T:Molecular mechanism of metabolic syndrome X:contribution of adipocytokines adipocytederived bioactive substances. Ann NY Acad Sci 892:146-154, 1999 (PMID:10842660)
 
2) Funahashi T, Nakamura T, Shimomura I et al:Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38:202-206, 1999 (PMID:10225688)
 
3) Seckl JR, Walker BR:11 beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142:1371-1376, 2001 (PMID:11250914)
 
4) Rask E, Olsson T, Soderberg S:Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421, 2001 (PMID:11238541)
 
5) Masuzaki H, Paterson J, Shinyama H et al:A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170, 2001 (PMID:11739957)
 
6) Maeda K, Okubo K, Shimomura I et al:Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227-235, 1997 (PMID:9197538)
 
7) Fukuhara A, Matsuda M, Nishizawa M et al:Visfatin:A protein secreted by visceral fat that mimics the effect of insulin. Science 307:426-430, 2005 (PMID:15604363)
 
8) Shimomura I, Funahashi T, Takahashi M et al:Enhanced expression of PAI-1 in visceral fat:Possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996 (PMID:8673927)
 
9) Samad F, Yamamoto K, Pandey M et al:Elevated expression of transforming growth factor-βin adipose tissue from obese mice. Mol Med 3:37-48, 1997 (PMID:9132278)
 
10) Ma LJ, Mao SL, Taylor KL et al:Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336-346, 2004 (PMID:14747283)
 
11) Hotamisligil GS, Shargill NS, Spiegelman BM:Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993 (PMID:7678183)
 
12) Hotamisligil GS, Peraldi P, Budavari A et al:IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271:665-668, 1996 (PMID:8571133)
 
13) Weisberg SP, McCann D, Desai M et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003 (PMID:14679176)
 
14) Xu H, Barnes GT, Yang Q et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003 (PMID:14679177)
 
15) Zhang Y, Proenca R, Maffei M et al:Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994 (PMID:7984236)
 
16) Shimomura I, Hammer RE, Ikemoto S et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999 (PMID:10485707)
 
17) Shimomura I, Matsuda M, Hammer RE et al:Decreased IRS-2 and SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6:77-86, 2000 (PMID:10949029)
 
18) Minokoshi Y, Kim YB, Peroni OD et al:Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339-343, 2002 (PMID:11797013)
 
19) Arita Y, Kihara S, Ouchi N et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999 (PMID:10092513)
 
20) Nishizawa H, Shimomura I, Kishida K et al:Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734-2741, 2002 (PMID:12196466)
 
21) Yamauchi T, Kamon J, Waki H et al:The fat derived hormone adiponectin reverses in sulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001 (PMID:11479627)
 
22) Maeda N, Shimomura I, Kishida K et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002 (PMID:12068289)
 
23) Okamoto Y, Kihara S, Ouchi N et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002 (PMID:12451000)
 
24) Matsuda M, Shimomura I, Sata M et al:Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487-37491, 2002 (PMID:12138120)
 
25) Yamauchi T, Kamon J, Minokoshi Y et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002 (PMID:12368907)
 
26) Wong Gw, Wong J, Hug C et al:A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci USA 8:10302-10307, 2004 (PMID:15231994)
 
27) Lindsay RS, Funahashi T, Hanson RL et al:Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002 (PMID:12114044)
 
28) Kumada M, Kihara S, Sumitsuji S et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003 (PMID:12524229)
 
29) Pischon T, Girman CJ, Hotamisligil GS et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004 (PMID:15082700)
 
30) Furukawa S, Fujita T, Shimabukuro M et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004 (PMID:15599400)
 
P.36 掲載の参考文献
1) Gaede P, Vedel P, Larsen N et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003 (PMID:12556541)
 
2) Reaven GM:Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988 (PMID:3056758)
 
3) Yamada N, Yoshinaga H, Sakurai N et al:Increased risk factors for coronary artery disease in Japanese subjects with hyperinsulinemia or glucose intolerance. Diabetes Care 17:107-114, 1994 (PMID:8137680)
PubMed
4) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001 (PMID:11368702)
 
5) Part I:Diagnosis and Classification of Diabetes Mellitus, In:Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. World Health Organization, Geneva, 1999
PubMed

Part 2 メタボリックシンドロームにおける脂質代謝異常―動脈硬化性疾患の予防における高脂血症治療の根拠を探る―

P.40 掲載の参考文献
1) Executive Summary of the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001 (PMID:11368702)
 
2) Part I:Diagnosis and Classification of Diabetes Mellitus. In:Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, World Health Organization, Geneva, 1999
PubMed
P.46 掲載の参考文献
1) Hokanson JE, Austin MA:Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level:a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219, 1996 (PMID:8836866)
 
2) Assman G, Schulte H, von Eckardstein A:Hypertriglyceridemia and elevated lipoprotein are risk factors for major coronary events in middle-aged men. Am J Cardiol 77:1179-1184, 1996 (PMID:8651092)
 
3) Stampfer MJ, Krauss RM, Ma J et al:A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888, 1996 ( PMID:8782637)
 
4) Matsuzaki M, Kita T, Mabuchi H et al, the J-LIT study group:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66:1087-1095, 2002 (PMID:12499611)
 
5) Iso H, Naito Y, Sato S et al:Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153:490-499, 2001 (PMID:11229681)
 
6) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive Summary of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001 (PMID:11368702)
 
7) Part I:Diagnosis and Classification of Diabetes Mellitus. In:Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, World Health Organization, Geneva, 1999
PubMed
8) Kataoka H, Kume N, Miyamoto S et al:Oxidized LDL modulates Bax/Bcl-2 through the lectinelike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21:955-960, 2001 (PMID:11397703)
 
9) Miyashita Y, Shirai K, Ito Y et al:Cytotoxicity of some oxysterols on human smooth muscle cells was mediated by apoptosis. J Atheroscler Thromb 4:73-78, 1997 (PMID:9638517)
 
10) Kugiyama K, Sakamoto T, Misumi I et al:Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 73:335-343, 1993 (PMID:8330376)
 
11) Doi H, Kugiyama K, Oka H et al:Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 102:670-676, 2000 (PMID:10931808)
 
12) Shirai K, Itoh Y, Sasaki H et al:The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35-41, 1999 (PMID:10580614)
 
13) Hitsumoto T, Ohsawa H, Uchi T et al:Preheparin lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 153:391-396, 2000 (PMID:11164428)
 
P.55 掲載の参考文献
1) Sasai K, Okumura-Noji K, Hibino T et al:Human cholesteryl ester transfer protein measured by enzyme-linked immunosorbent assay with two monoclonal antibodies against rabbit cholesteryl ester transfer protein:Plasma cholesteryl ester transfer protein and lipoproteins among Japanese hypercholesterolemic patients. Clin Chem 44:1466-1473, 1998 (PMID:9665425)
 
2) Goto A, Sasai K, Suzuki S et al:Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects:a study based on coronary angiography. Atheroscelrosis 159:153-163, 2001 (PMID:11689217)
 
3) Matsuzaki M, Kita T, Mabuchi H et al, J-LIT Study Group:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66:1087-1095, 2002 (PMID:12499611)
 
4) Schulzeck P, Bojanovski M, Jochim A et al:Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet i (8586):611-613, 1988 (PMID:2894548)
 
5) Yokoyama S:Treatment of hypercholesterolemia by chemical adsorption of lipoproteins (review). J Clin Apheresis 4:66-71, 1988 (PMID:2456283)
 
6) Yokoyama S:Release of cellular cholesterol:Molecular mechanism for cholesterol homeostasis in cells and in the body (review). Biochim Biophys Acta 1529:231-244, 2000 (PMID:11111029)
 
7) Francis GA, Knopp RH, Oram JF:Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Invest 96:78-87, 1995 (PMID:7615839)
 
8) Brooks-Wilson A, Marcil M, Clee SM et al:Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336-345, 1999 (PMID:10431236)
 
9) Bodzioch M, Orso E, Klucken J et al:The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22:347-351, 1999 (PMID:10431237)
 
10) Rust S, Rosier M, Funke H et al:Tangier disease is caused by mutations in the gene encoding ATP binding-cassette transporter 1. Nat Genet 22:352-355, 1999 (PMID:10431238)
 
11) Tsujita M, Yokoyama S:Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol. Biochemistry 35:13011-13020, 1996 (PMID:8855936)
 
12) Tsujita M, Tomimoto S, Okumura-Noji K et al:Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice. Biochim Biophys Acta 1485:199-213, 2000 (PMID:10832100)
 
13) Tomimoto S, Tsujita M, Okazaki M et al:Effect of probucol in lecithin-cholesterol acyltransferase deficient mice:Inhibition of two independent cellular cholesterol releasing pathways in vivo. Arterioscler Thromb Vasc Biol 21:394-400, 2001 (PMID:11231919)
 
14) Wu CA, Tsujita M, Hayashi M et al:Probucol Inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and for its proteolytic degradation. J Biol Chem 279:30168-30174, 2004 (PMID:15140889)
 
15) Abe-Dohmae S, Suzuki S, Wada Y:Characterization of apolipoprotein-mediated HDL generation induced by cAMP in a murine macrophage cell line. Biochemistry 39:11092-11099, 2000 (PMID:10998247)
 
16) Oram JF, Lawn RM, Garvin MR et al:ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 275:34508-34511, 2000 (PMID:10918070)
 
17) Santamarina-Fojo S, Peterson K, Knapper C et al:Complete genomic sequence of the human ABCA1 gene:analysis of the human and mouse ATP-binding cassette A promoter. Proc Natl Acad Sci USA 97:7987-7992, 2000 (PMID:10884428)
 
18) Costet P, Luo Y, Wang N et al:Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275:28240-28245, 2000 (PMID:10858438)
 
19) Chinetti G, Lestavel S, Bocher V et al:PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001 (PMID:11135616)
 
20) Chawla A, Boisvert WA, Lee CH et al:A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171, 2001 (PMID:11172721)
 
21) Repa JJ, Turley SD, Lobaccaro JA et al:Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289:1524-1529, 2000 (PMID:10968783)
 
22) Francis GA, Oram JF, Heinecke Jw et al:Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry 35:15188-15197, 1996 (PMID:8952466)
 
23) Inazu A, Brown ML, Hesler CB et al:Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234-1238, 1990 (PMID:2215607)
 
24) Marotti KR, Castle CK, Boyle TP:Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364:73-75, 1993 (PMID:8316302)
 
25) Sugano M, Makino N, Sawada S et al:Effect of antisence oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 273:5033-5036, 1998 (PMID:9478952)
 
26) Okamoto H, Yonemori F, Wakitani K et al:A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203-207, 2000 (PMID:10910363)
 
27) Zhong S, Sharp DS, Grove JS et al:Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97:2917-2923, 1996 (PMID:8675707)
 
28) Hirano K, Yamashita S, Kuga Y et al:Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 15:1849-1856, 1995 (PMID:7583564)
 
29) Ko KW, Ohnishi T, Yokoyama S:Triglyceride transfer is required for net cholesteryl ester transfer between lipoproteins in plasma by lipid transfer protein. Evidence for a hetero-exchange mechanism demonstrated by using novel monoclonal antibodies. J Biol Chem 269:28206-28213, 1994 (PMID:7961758)
 
30) Sparrow CP, Pittman RC:Cholesterol esters selectively taken up from high-density lipoproteins are hydrolyzed extralysosomally, Biochim Biophys Acta 1043:203-210, 1990 (PMID:2317530)
 
31) Acton S, Rigotte A, Landschulz KT et al:Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271:518-520, 1996 (PMID:8560269)
 
32) Kozarsky KF, Donahee, MH, Rigotti A et al:Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 387:414-417, 1997 (PMID:9163428)
 
33) Rigotti A, Trigatti BL, Penman M et al:A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl A cad Sci USA 94:12610-12615, 1997 (PMID:9356497)
 
34) Ikemoto M, Arai H, Feng D et al:Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I. Proc Natl Acad Sci USA 97:6538-6543, 2000 (PMID:10829064)
 
35) Mardones P, Pilon A, Bouly M et al:Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem 278:7884-7890, 2003 (PMID:12511553)
 
36) Moestrup SK, Kozyraki R, Kristiansen M et al:The Intrinsic Factor-Vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J Biol Chem 273:5235-5242, 1998 (PMID:9478979)
 
37) Hammad SM, Stefansson S, Twal WO et al:Cubilin, the endocytic receptor for intrinsic factor-vitamin B12 complex, mediates high-density lipoprotein holoparticle endocytosis. Proc Natl Acad Sci USA 96:10158-10163, 1999 (PMID:10468579)
 
38) Kozyraki R, Fyfe J, Kristiansen M et al:The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 5:656-661, 1999 (PMID:10371504)
 
39) Hammad SM, Barth JL, Knaak C et al:Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem 275:12003-12008, 2000 (PMID:10766831)
 
40) Aminoff M, Carter JE, Chadwick RB et al:Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1. Nat Genet 21:309-313, 1999 (PMID:10080186)
 
P.63 掲載の参考文献
1) Isomaa B, Almgren P, Tuomi T et al:Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001 (PMID:11315831)
 
2) 山田信博:Metabolic syndrome:診断と治療の進歩. 疾患概念. 歴史と疾患概念. 日本内科学会雑誌 93:635-641, 2004
 
3) Mahley Rw, Huang Y, Rall SC Jr et al:Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, Quandaries, and paradoxes. J Lipid Res 40:1933-1949, 1999 (PMID:10552997)
 
4) 井上由香利, 山田信博:レムナントリポタンパク. 内科 93:1109-1110, 2004
 
5) Phillips NR, Waters D, Havel RJ:Plasma lipoploteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 88:2762-2770, 1993 (PMID:8252689)
 
6) Krauss RM, Lindgren FT, Williams PT et al:Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lanect ii:62-66, 1987 (PMID:2885572)
 
7) Nakajima K, Saito T, Tamura A et al:Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and anti apoA-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993 (PMID:8143370)
 
8) Mahley RW:Atherogenic lipoproteins and coronary artery disease:concepts derived from recent advances in cellular and molecular biology. Circulation 72:943-948, 1985 (PMID:4042302)
 
9) Kugiyama K, Doi H, Takazoe K et al:Remnant lipoprotein levels in fasting serum predictcoronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999 (PMID:10359727)
 
10) Kameda K, Matsuzawa Y, Kubo M et al:Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis 51:241-249, 1984 (PMID:6743382)
 
11) Shaikh M, Wootton R, Nordestgaard BG et al:Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in human. Artherioscler Throneb 11:567-577, 1991 (PMID:2029497)
 
12) Karpe F, Boquist S, Tang R et al:Remnant lipoproteins are related to intima-media thickness of the carotid artery independenty of LDL cholesterol and plasma triglycerides. J Lipid Res 42:17-21, 2001 (PMID:11160361)
 
13) Gronholdt ML, Nordestgaard BG, Wiebe BM et al:Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceriderich lipoproteins as well as increased plaque content. Circulation 97:34-40, 1998 (PMID:9443429)
 
14) McNamara JR, Shah PK, Nakajima K et al:Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women:results from the Framingham Heart Study. Artherosclerosis 154:229-236, 2001 (PMID:11137104)
 
15) Yagyu H, Ishibashi S, Chen Z et al:Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. J Lipid Res 40:1677-1685, 1999 (PMID:10484615)
 
16) Ishibashi S, Brown MS, Goldstein JL et al:Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92:883-893, 1993 (PMID:8349823)
 
17) Ishibashi s, Goldstein JL, Brown Ms et al:Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 93:1885-1893, 1994 (PMID:8182121)
 
18) Ishibashi s, Herz J, Maeda N et al:The two-receptor model of lipoprotein clearance:tests of the hypotheisis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 91:4431-4435, 1994 (PMID:8183926)
 
19) Ishibashi S, Perrey S, Chen Z et al:Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnats. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem 271:22422-22427, 1996 (PMID:8798405)
 
20) Shimada M, Ishibashi S, Inaba T et al:Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci USA 93:7242-7246, 1996 (PMID:8692976)
 
P.70 掲載の参考文献
1) Chen GC, Liu W, Duchateau P et al:Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). Association of altered proteolytic accesibility with decreased receptor binding of LDL subspeices from hypertriglyceridemic subjects. J Biol Chem 269:29121-29128, 1994 (PMID:7961878)
 
2) Galeano NF, Milne R, Marcel YL et al:Apoprotein-B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 269:511-519, 1994 (PMID:8276844)
PubMed
3) Galeano NF, Al-Haideri M, Keyserman F et al:Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites:apotential mechanism for increased atherogenicity. J Lipid Res 39:1263-1273, 1998 (PMID:9643358)
 
4)Austin MA, Breslow JL, Hannekens CH et al:Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988 (PMID:3418853)
 
5) Koba S, Hirano T:Small dense low-density lipoprotein in Japanese men with coronary artery disease. Ann Intern Med 132:762, 2000 (PMID:10787380)
 
6) Koba S, Hirano T, Yoshino G et al:Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes. Atherosclerosis 160:249-256, 2002 (PMID:11755944)
 
7) Feingold KR, Grunfeld C, Pang M et al:LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. J Arterioscler Thromb 12:1496-1502, 1992 (PMID:1450181)
 
8) Suehiro T, Ohguro T, Sumiyoshi R et al:Relationship of low-density lipoprotein particle size to plasma lipoproteins, obesity, and insulin resistance in Japanese men. Diabetes care 18:333-338, 1995 (PMID:7555476)
 
9) Griffin BA, Freeman DJ, Tait GW et al:Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions:relative contribution of small dense LDL to coronary heart disease risk. Artherosclerosis 106:241-253, 1994 (PMID:8060384)
 
10) Kazumi T, Kawaguchi A, Hozumi T et al:Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Artherosclerosis 142:113-119, 1999 (PMID:9920512)
 
11) Hirano T, Naito H, Kurokawa M et al:High prevalence of small LDL particles in non-insulin dependent diabetic patients with nephropathy. Atherosclerosis 123:57-72, 1996 (PMID:8782837)
 
12) 平野勉, 鹿住敏, 芳野原:小粒子高比重LDL-注目される新しい動脈硬化の危険因子. 高脂血症と動脈硬化. 別冊医学のあゆみ:173-177, 2002
 
13) Kazumi T, Kawaguchi A, Sakai K et al:Young men with high-normal blood pressue have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25:971-976, 2002 (PMID:12032101)
 
14) Barakat HA, McLendon VD, Marks R et al:Influence of morbid obesity and non-insulin dependent diabetes mellitus on high density lipoprotein composition and sub-population distribution. Metabolism 41:37-41, 1992 (PMID:1538644)
 
15) 竹本昌代, 芳野原, 佐藤裕子ほか:高度肥満女性の食事内容の特徴と血中脂質-減量に対する変化の観察. 肥満研究 4:282-286, 1998
Medical*Online
16) Wakatsuki A, Ikenoue N, Shinohara K et al:Small low-density lipoprotein particles and endothelium-dependent vasodilatation in post-menopausal women. Atherosclerosis 177:329-336, 2004 (PMID:15530907)
 
17) Lemieux I, Almeras N, Mauriege P et al:Prevalence of'hypertriglyceridemic waist' in men who participated in the Quebec Health Survey:association with atherogenic and diabetogenic metabolic risk factors. Can J Cardiol 18:725-732, 2002 (PMID:12167959)
 
18) Krauss RM, Burke DJ:Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23:97-104, 1982
PubMed
19) 三島康男, 安藤充, 久山文子ほか:簡便なPAG電気泳動キット(Lipo Phor system)を用いたLDL粒子サイズの推定:LipoPrint LDL systemとの比較. 動脈硬化 25:67-70, 1997
 
20) Hirano T, Ito Y, Saegusa H et al:A novel and simple method for quantification of small, dense LDL. J Lipid Res 44:2193-2201, 2003 (PMID:12897184)
 
21) Hirano T, Ito Y, Koba S et al:Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 24:558-563, 2004 (PMID:14726414)
 
22) Yoshino G, Hirano T, Kazumi T:Treatment of small dense LDL. J Atheroscler Thromb 9:266-275, 2002 (PMID:12560585)
 

Part 3 メタボリックシンドロームとPPARの関連性―PPARの機能を探る―

P.80 掲載の参考文献
1) Marx N, Duez H, Fruchart JC et al:Peroxisome proliferator-activated receptors and atherogenesis:regulators of gene expression in vascular cells. Circ Res 94:1168-1178, 2004 (PMID:15142970)
 
2) Plutzky J:The potential role of perioxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 92:34J-41J, 2003 (PMID:12957325)
 
3) Ziouzenkova O, Perrey S, Asatryan L et al:Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands:evidence for an anti-inflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 100:2730-2735, 2003 (PMID:12606719)
 
4) Kersten S, Seydoux J, Peters JM et al:Peroxisome proliferators-activated receptor α mediates the adaptive response to fasting. J Clin Invest 103:1489-1498, 1999 (PMID:10359558)
 
5) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes:the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:9055-910, 2001 (PMID:11289345)
 
6) Faergeman O:Hypertriglyceridemia and the fibrate trials. Curr Opin Lipidol 11:609-614, 2000 (PMID:11086334)
 
7) Frick MH, Syvanne M, Nieminen MS et al:Prevention of the angiographic progresson of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96:2137-2143, 1997 (PMID:9337181)
 
8) Delerive P, De Bosscher K, Besnard S et al:Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-KB and AP-1. J Biol Chem 274:32048-32054, 1999 (PMID:10542237)
 
9) Marx N, Sukhova GK, Collins T et al:PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131, 1999 (PMID:10377075)
 
10) Delerive P, Gervois P, Fruchart JC et al:Induction of IKBα expression as a mechanism contributing to the anti-inflammaoty activities of peroxisome proliferator-activated receptor α activators. J Biol Chem 275:36703-36707, 2000 (PMID:10980195)
 
11) Lee H, Shi W, Tontonoz P et al:Role for peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 87:516-521, 2000 (PMID:10988245)
 
12) Chinetti G, Lestavel S, Bocher V et al:PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001 (PMID:11135616)
 
13) Hsueh WA, Bruemmer D:Peroxisome proliferator-activated receptorγ:implications for cardiovascular disease. Hypertension 43:297-305, 2004 (PMID:14732733)
 
14) Jiang c, Ting AT, Seed B:PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998 (PMID:9422509)
 
15) Oliver WR Jr, Shenk JL, Snaith MR et al:A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311, 2001 (PMID:11309497)
 
16) Lee CH, Chawla A, Urbiztondo N et al:Transcriptional repression of atherogenic inflammation:modulation by PPARδ. Science 302:453-457, 2003 (PMID:12970571)
 
17) Plutzky J:Medicine. PPARs as therapeutic targets:reverse cardiology? Science 302:406-407, 2003 (PMID:14563997)
 
P.86 掲載の参考文献
1) Li AC, Glass CK:PPAR-and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45:2161-2173, 2004 (PMID:15489539)
 
2) Reddy JK, Hashimoto T:Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha:an adaptive metabolic system. Ann Rev Nutr 21:193-230, 2001 (PMID:11375435)
 
3) Patsouris D, Mandard S, Voshol PJ et al:PPAR alpha governs glycerol metabolism. J Clin Invest 114:94-103, 2004 (PMID:15232616)
 
4) Kersten S, Seydoux J, Peters JM et al:Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103:1489-1498, 1999 (PMID:10359558)
 
5) Kuriyama H, Kawamoto S, Ishida N et al:Molecular cloning and expression of a novel human aquaporin from adipose tissue with glycerol permeability. Biochem Biophys Res Commun 241:53-58, 1997 (PMID:9405233)
 
6) Kishida K, Kuriyama H, Funahashi T et al:Aquaporin adipose, a putative glycerol channel in adipocytes. J Biol Chem 275:20896-20902, 2000 (PMID:10777495)
 
7) Kuriyama H, Shimomura I, Kishida K et al:Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes 51:2915-2921, 2002 (PMID:12351427)
 
8) Maeda N, Funahashi T, Hibuse T et al:Adaptation to fasting by glycerol transport through aquaporin 7 in adipose tissue. Proc Natl Acad Sci USA 101:17801-17806, 2004 (PMID:15591341)
 
9) Rodriguez de Fonseca F, Navarro M, Gomez R et al:An anorexic lipid mediator regulated by feeding. Nature 414:209-212, 2001 (PMID:11700558)
 
10) Fu J, Gaetani S, Oveisi F et al:Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90-93, 2003 (PMID:12955147)
 
11) Rosen ED:Energy balance:a new role for PPAR alpha. Curr Biol 13:R961-R963, 2003 (PMID:14680654)
 
12) Schoonjans K, Watanabe M, Suzuki H et al:Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by aperoxisome proliferator response element in the C promoter. J Biol Chem 270:19269-19276, 1995 (PMID:7642600)
 
13) Motojima K, Passilly P, Peters JM et al:Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue and inducer-specific manner. J Biol Chem 273:16710-16714, 1998 (PMID:9642225)
 
14) Rodriguez JC, Gil-Gomez G, Hegardt FG et al:Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase geneby fatty acids. J Biol Chem 269:18767-18772, 1994 (PMID:7913466)
 
15) Berthou L, Duverger N, Emmanuel F et al:Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97:2408-2416, 1996 (PMID:8647932)
 
16) Vu-Dac N, Chopin-Delannoy S, Gervois P et al:The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erb α mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273:25713-25720, 1998 (PMID:9748239)
 
17) Marx N, Sukhova GK, Collins T et al:PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131, 1999 (PMI:10377075)
 
18) Staels B, Koenig W, Habib A et al:Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393:790-793, 1998 (PMID:9655393)
 
19) Chinetti G, Lestavel S, Bocher V et al:PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001 (PMID:11135616)
 
20) Chinetti G, Gbaguidi FG, Griglio S et al:CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101:2411-2417, 2000 (PMID:10821819)
 
21) Chinetti G, Lestavel S, Fruchart JC et al:Peroxisome proliferator-activated receptor α reduces cholesterol esterification in macrophages. Circ Res 92:212-217, 2003 (PMID:12574149)
 
22) Fischer M, You M, Matsumoto M et al:Peroxisome proliferator-activated receptor α (PPARα) agonist treatment reverses PPARα dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 278:27997-28004, 2003 (PMID:12791698)
 
23) You M, Fischer M, Deeg MA et al:Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 277:29342-29347, 2002 (PMID:12036955)
 
24) You M, Crabb DW:Recent advances in alcoholic liver disease II. Minireview:molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol 287:G1-G6, 2004 (PMID:15194557)
 
25) Nakajima T, Kamijo Y, Tanaka N et al:Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage. Hepatology 40:972-980, 2004 (PMID:15382117)
 
P.93 掲載の参考文献
1) Issemann I, Green S:Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650, 1990 (PMID:2129546)
 
2) Kersten S, Desvergne B, Wahli W:Roles of PPARs in health and disease. Nature 405:421-424, 2000 (PMID:10839530)
 
3) Yamauchi T, Kamon J, Waki H et al:The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 276:41245-41254, 2001 (PMID:11533050)
 
4) Sarraf P, Mueller E, Jones D et al:Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 4:1046-1052, 1998 (PMID:9734398)
 
5) Wang YX, Lee CH, Tiep S et al:Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113:159-170, 2003 (PMID:12705865)
 
6) Tontonoz P, Hu E, Spiegelman BM:Stimulation of adipogenesis in fibroblasts by PPARγ 2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994 Erratum in:Cell 80:following 957, 1995 (PMID:8001151)
 
7) Kubota N, Terauchi Y, Miki H et al:PPARγ mediates high-fat diet-induced adipocyte hyper, trophy and insulin resistance. Mol Cell 4:597-609, 1999
 
8) Okuno A, Tamemoto H, Tobe K et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998 (PMID:9502777)
 
9) Kallen CB, Lazar MA:Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci 93:5793-5796, 1996 (PMID:8650171)
 
10) Hollenberg AN, Susulic VS, Madura JP et al:Functional antagonism between CCAAT/Enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter. J Biol Chem 272:5283-5290, 1997 (PMID:9030601)
 
11) Yamauchi T, Kamon J, Minokoshi Y et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002 (PMID:12368907)
 
12) Hara K, Okada T, Tobe K et al:The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212-216, 2000 (PMID:10777704)
 
13) Deeb SS, Fajas L, Nemoto M et al:A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287, 1998 (PMID:9806549)
 
14) Mori H, Ikegami H, Kawaguchi Y et al:The Pro12→Ala Substitution in PPAR-γis associated With Resistance to Development of Diabetes in the General Population:Possible Involvement in Impairment of Insulin Secretion in Individuals With Type 2 Diabetes. Diabetes 50:891-894, 2001 (PMID:11289058)
 
15) Ebisawa M, Umemiya H, Ohta K et al:Retinoid X receptor-antagonistic diazepinylbenzoic acids. Chen Pharm Bull (Tokyo) 47:1778-1786, 1999 (PMID:10748721)
 
16) Yamauchi T, Waki H, Kamon J et al Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013, 2001 (PMID:11581301)
 
P.98 掲載の参考文献
1) Escher P, Braissant O, Basu-Modak S et al:Rat PPARs:quantitative analysis in adult rat tissue sand regulation in fasting and refeeding. Endocrinology 142:4195-4202, 2001 (PMID:11564675)
 
2) Grimaldi PA:The roles of PPARs in adipocyte differentiation. Prog Lipid Res 40:269-281, 2001 (PMID:11412892)
 
3) Amri EZ, Bonino F, Aihaud G et al:Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. J Biol Chem 270:2367-2371, 1995 (PMID:7836471)
 
4) Bastie C, Holst D, Gaillard D et al:Expression of peroxisome proliferator-activated receptor PPARδ promotes induction of PPARγ and adipocyte differentiation in 3T3C2 fibroblasts. J Biol Chem 274:21920-21925, 1999 (PMID:10419513)
 
5) Bastie C, Luquet S, Holst D et al:Alterations of peroxisome proliferator-activated receptor δ activity affect fatty acid-controlled adipose differentiation. J Biol Chem 275:38768-38773, 2000 (PMID:10991946)
 
6) Jehl-Pietri C, Bastie C, Gillot I et al:Peroxisome-proliferator-activated receptor δ mediated the effects of long-chain fatty acids on post-confluent cell proliferation. Biochem J 350:93-98, 2000 (PMID:10926831)
 
7) Hansen JB, Zhang H, Rasmussen TH et al:Peroxisome proliferator-activator δ (PPARδ)-mediated regulation of preadipocyte proliferation and gene expression is depent on cAMP signaling. J Biol Chem 276:3175-3182, 2001 (PMID:11069900)
 
8) Peters JM, Lee SS, Li W et al:Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β (δ). Mol Cell Biol 20:5119-5128, 2000 (PMID:10866668)
 
9) Barak Y, Liao D, He W et al:Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303-308, 2002 (PMID:11756685)
 
10) Lee CH, Chawla A, Urbiztond N et al:Transcriptional repression of atherogenic inflammation:modulation by PPARδ. Science 302:453-457, 2003 (PMID:12970571)
 
11) Wang YX, Lee CH, Tiep S et al:Peroxisome proliferators-activated receptor-δ activates fat metabolism to prevent obesity. Cell 113:159-170, 2003 (PMID:12705865)
 
12) Tanaka T, Yamamoto J, Iwasaki S et al:Activation of peroxisome proliferator-activated receptor-δinduces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924-15929, 2003 (PMID:14676330)
 
13) Luquet S, Lopez-Soriano J, Holst D et al:Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB J 17:2299-2301, 2003 (PMID:14525942)
 
14) Wang YX, Zhang CL, Yu RT et al:Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol 2:e294, 2004 (PMID:15328533)
 
15) Gupta RA, Wang D, Katkuri S et al:Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat Med 10:245-247, 2004 (PMID:14758356)
 
16) Harman FS, Nicol CJ, Marin HE et al:Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat Med 10:481-483, 2004 (PMID:15048110)
 

Part 4 PPARαアゴニストとしてのフィブラートの役割―メタボリックシンドロームにおけるフィブラートの有用性を探る―

P.108 掲載の参考文献
1) Tanaka T, Yamamoto J, Iwasaki S et al:Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924-15929, 2003 (PMID:14676330)
 
2) 井上郁夫:PPARα. Mebio 21(12):9-20, 2004
 
3) 井上郁夫, 片山茂裕, 山田信博:PPARαと脂質代謝. Progress in Medicine 19:2451-2459, 1999
Medical*Online
4) Inoue I, Katayama S:The possible therapeutic actions of peroxisome proliferator-activated receptor α (PPARα) agonists, PPAR γ agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium (Ca)-antagonists on vascular endothelial cells. Curr Drug Targets Cardiovasc Haeneatol Disord 4:35-52, 2004 (PMID:15032651)
 
5) 井上郁夫:PPAR リガンドの抗動脈硬化作用. 細胞 36:98-103, 2004
 
6) Inoue I, Shino K, Noji S et al:Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246:370-374, 1998 (PMID:9610365)
 
7) Inoue I, Hayashi K, Yagasaki F et al:Apoptosis of endothelial cells may be mediated by genes of peroxisome proliferator-activated receptor γ1 (PPARγ 1) and PPARα genes. J Atheroscler Thomb 10:99-108, 2003 (PMID:12740484)
 
8) Inoue I, Koh HS, Mizotani K et al:A patient with severe hypertriglyceridemia associated with anemia and hypoalbuminemia. J Atheroscler Thomb 1O:192-201, 2003
 
9) Anderson LM, Choe SE, Yukhananov RY et al:Identification of a novel set of genes regulated by a unique liver X receptor α-mediated transcription mechanism. J Biol Chem 278:15252-15260, 2003 (PMID:12551904)
 
10) Zhao A, Lew JL, Huang L et al:Human kininogen gene is transactivated by the farnesoid X receptor. J Biol Chem 278:28765-28770, 2003 (PMID:12761213)
 
11) Shimamoto Y, Hirota K, Fukamizu A:Effect of peroxisome proliferator-activated receptor α on human angiotensinogen promoter. Int J Mol Med 13:729-733, 2004
 
12) Griendling KK:Novel NAD (P) H oxidases in the cardiovascular system. Heart 90:491-493, 2004 (PMID:15067378)
 
13) Schupp M, Janke J, Clasen R et al:Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor γ activity. Circulation 109:2054-2057, 2004 (PMID:15117841)
 
14) Tenenbaum A, Motro M, Fisman EZ et al:Peroxisome proliferator-activated ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109:2197-2202, 2004 (PMID:15123532)
 
15) Jonkers IJ, deMan FH, van der Laarse A et al:Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens 19:749-755, 2001 (PMID:11330878)
 
16) Kim JI, Tsujino T, Fujioka Y et al:Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res 26:307-313, 2003 (PMID:12733699)
 
P.113 掲載の参考文献
1) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 285:2486-2497, 2001 (PMID:11368702)
 
2) Austin MA, Breslow JL, Hennekens CH et al:Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988 (PMID:3418853)
 
3) Hirano T, Yoshino G, Kazumi T:Troglitazone and small low-density lipoprotein in Type 2 diabetes. Ann Intern Med 129:162-163, 1998 (PMID:9669982)
 
4) Nakajima K, Saito T, Tamura A et al:cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993 (PMID:8143370)
 
5) 田中明, 沼野藤夫, 江尻成昭:動脈硬化疾患におけるRLP-コレステロール(レムナント様リポ蛋白-コレステロール)測定の臨床的意義. Progressive in Medicine 13:1215-1222, 1993
 
6) Kugiyama K, Doi H, Takazoe K, et al:Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999 (PMID:10359727)
 
7) 久木山清貴:脂質代謝異常の検査のとらえ方と心血管リスク. 日本内科学会雑誌 93:683-689, 2004
 
P.120 掲載の参考文献
1) Otvos JD, Jeyarajah EJ, Bennett Dw et al:Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38:1632-1638, 1992 (PMID:1326420)
 
2) Otvos JD:Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48:171-180, 2002 (PMID:11934219)
 
3) Ikewaki K, Noma K, Tohyama J et al:Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia-a nuclear magnetic resonance study. Int J Cardiol, 2005 (in press)
 
4) Schonfeld G:The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 111:161-174, 1994 (PMID:7718018)
 
5) Totsuka M, Miyashita Y, Ito Y et al:Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis 153:75-179, 2000 (PMID):11058713)
 
6) Homma Y, Ozawa H, Kobayashi T et al:Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-densitylipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 106:191-201, 1994 (PMID:8060379)
 
7) Packard CJ, Shepherd J:Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17:3542-3556, 1997 (PMID:9437204)
 
P.128 掲載の参考文献
1) 田中明, 加藤徹, 石橋俊ほか:食後高脂血症に及ぼす抗高脂血症薬の影響. Prog Med 24:1293-1302, 2004
Medical*Online
2) Zilversmit DB:Atherogenesis:a postprandial phenomenon. Circulation 60:473-485, 1979 (PMID:222498)
 
3) Tanaka A, Ejiri N, Fujinuma Y et al:Remnant like particles and restenosis of coronary arteries after PTCA. Ann NY Acad Sci 748:595-598, 1995 (PMID:7695211)
 
4) Iso H, Naito Y, Sato S et al:Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153:490-499, 2001 (PMID:11226981)
 
5) Eberly LE, Stamler J, Neaton JD et al, Multiple Risk Factor Intervention Trial Research Group:Relation of triglyceride levels, fasting and non. fasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 163:1077-1083, 2003 (PMID:12742806)
 
6) Tanaka A, Tomie N, Nakano T et al:Measurement of postprandial remnant-like particles (RLPs) following a fat-loading test. Clin Chim Acta 275:43-52, 1998 (PMID:9706842)
 
7) Kinoshita M, Kojima M, Matsushima T et al:Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 351:115-120, 2005 (PMID:15563879)
 
P.135 掲載の参考文献
1) Austin MA, Breslow JL, Hennekens CH et al:Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988 (PMID:3418853)
 
2) Austin MA, King MC, Vranizan KM et al:Atherogenic lipoprotein phenotype:a proposed genetic marker coronary heart disease risk. Circulation 82:495-506, 1990 (PMID:2372896)
 
3) Griffin BA, Packard CJ:Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 5:200-206, 1994 (PMID:7952914)
 
4) Ikeda Y:Mechanism of the production of small dense LDL in hypertriglyceridemia. In:Atherosclerosis ?, ed by Jacotot B et al, Elsevier science, Singapore, 1998, pp777-788
 
5) Zambon A, Austin MA, Brown BG et al:Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 13:147-153, 1993 (PMID:8427851)
 
6) Hirano T, Oi K, Sakai S et al:High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage:a possible role of postprandial lipemia. Atherosclerosis 141:77-85, 1998 (PMID:9863540)
PubMed
7) Koba S, Hirano T, Murayama S et al:Small dense LDL phenotype is associated with post-prandial increases of large VLDL and remnant-like particles in patients with acute myocardial infarction. Atherosclerosis 170:131-140, 2003 (PMID:12957691)
 
8) Reaven GM, Chen YD, Jeppesen J et al:Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92:141-146, 1993 (PMID:8325978)
 
9) Hirano T, Yoshino G, Kazumi T:Troglitazone and small low-density lipoprotein in type 2 diabetes. Ann Intern Med 129:162-163, 1998 (PMID:9669982)
 
10) Packard CJ, Shepherd J:Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17:3542-3556, 1997 (PMID:9437204)
 
11) Berneis KK, Krauss RM:Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43:1363-1379, 2002 (PMID:12235168)
 
12) Austin MA, Mykkanen L, Kuusisto J et al:Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92:1770-1778, 1995 (PMID:7671360)
 
13) Kazumi T, Kawaguchi A, Sakai K et al:Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25:971-976, 2002 (PMID:12032101)
 
14) Hirano T, Kazumi T, Yoshino G:Long-term efficacy of bezafibrate on reducing small dense LDL by its hypotriglyceridemic action. Curr Ther Res 61:127-136, 2000
 
15) Vakkilainen J, Steiner G, Ansquer JC et al:Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease:the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107:1733-1737, 2003 (PMID:12665498)
 
16) Milosavljevic D, Griglio S, Le Naour G et al:Preferential reduction of very low densitylipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia:consequences for lipid accumulation in human monocyte-derived macrophages. Atheroscerosis 155:251-260, 2001 (PMID:11223449)
 
17) Tenenbaum A, Motro M, Fisman EZ et al:Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109:2197-2202, 2004 (PMID:15123532)
 
18) Hirano T, Ito Y, Saegusa H et al:A novel and simple method for quantification of small, dense LDL. Lipid Res 44:2193-2201, 2003 (PMID:12897184)
 
19) Hirano T, Ito Y, Koba S et al:Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 24:558-563, 2004 (PMID:14726414)
 
20) Ikewaki K, Tohyama J, Nakata Y et al:Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men-a nuclear magnetic resonance study. J Atheroscler Thromb 11:278-285, 2004 (PMID:15557710)
 
P.143 掲載の参考文献
1) Gordon DJ, Probstfield JL, Garrison RJ et al:High-density lipoprotein cholesterol and cardiovascular disease; four prospective American studies. Circulation 79:8-15, 1989 (PMID:2642759)
 
2) 垂井清一郎:厚生省特定疾患原発性高脂血症調査研究班昭和62年度報告書, 1987
 
3) 板倉弘重, J-LIT研究会参加医:日本における大規模疫学試験からわかったこと J-LIT. The Lipid 12:239-247, 2001
 
4) von Eckardstein A, Nofer JR, Assmann G:High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13-27, 2001 (PMID:11145929)
 
5) Matsuyama A, Yamashita S, Sakai N et al:Identification of a GPI-anchored type HDL-binding protein on human macrophages. Biochem Biophys Res Commun 272:864-871, 2000 (PMID:10860843)
 
6) von Eckardstein A, Assmann G:Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol 11:627-637, 2000 (PMID:11086337)
 
7) Jones P, Kafonek S, Laurora I et al:Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 81:582-587, 1998 (PMID:9514454)
 
8) 第33回日本動脈硬化学会総会レポート;JLITのデータをもとにした『動脈硬化診療ガイドライン』の提案が話題に. Nikkei Medical 2001年8月号:132-139, 2001
 
9) Fruchart JC, Duriez P, Staels B et al:Peroxisome proliferator activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10:245-257, 1999 (PMID:10431661)
 
10) Fruchart JC, Staels B, Duriez P et al:The role of fibric acids in atherosclerosis. Curr Atherosclerosis Reports 3:83-92, 2001 (PMID:11123853)
 
11) Bouly M, Masson D, Gross B et al:Induction of the phospholipids transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem 276:25841-25847, 2001 (PMID:11342537)
 
12) Manninen V, Tenkanen L, Koskinen P et al:Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85:37-45, 1992 (PMID:1728471)
 
13) Rubins HB, Robins SJ, Collins D et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999 (PMID:10438259)
 
14) Manninen V, Elo MO, Frick MH et al:Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260:641-651, 1988 (PMID:3164788)
 
15) The BIP Study Group:Secondary preverntion by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21-27, 2000 (PMID:10880410)
 
16) Robins SJ, Collins D, Wittes JT et al:Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA 285:1585-1591, 2001 (PMID:11268266)
 
17) Schaefer EJ, Lamon-Fava S, Cole T et al:Effects of regular and extended release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. Atherosclerosis 127:113-122, 1996 (PMID:9006811)
 
18) Stampfer MJ, Sacks FM, Salrini S et al:A prospective study of cholesterol, apoproteins and risks of myocardial infarction. N Engl J Med 325:373-381, 1991 (PMID:2062328)
 
19) Sacks FM, Expert Group on HDL Cholesterol:The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease:expert group recommendations. Am J Cardiol 90:139-143, 2002 (PMID:12106843)
 
20) The FIELD Study Investigators:The need for a large-scale trial of fibrate therapy in diabetes:the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Diabetol 3:9, 2004 (PMID:15571637)
 
21) Chinetti G, Gbaguidi FG, Griglio S et al:CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Cirulation 101:2411-2417, 2000 (PMID:10821819)
 
22) Hirano K, Yamashita S, Nakagawa Y et al:Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 85:108-116, 1999 (PMID:10400916)
 
23) Tenenbaum A, Motro M, Fisman EZ et al:Peroxisome proliferators-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109:2197-2202, 2004 (PMID:15123532)
 
P.153 掲載の参考文献
1) 竹内宏, 斉藤重幸, 高木覚ほか:日本人男性におけるMetabolic syndromeとインスリン抵抗性の検討-端野・壮瞥研究-. 糖尿病 46:739-744, 2003
 
2) 森豊, 田峻尚子:代謝症候群における耐糖能異常の病態と早期診断の重要性. Medical Practice 21:2025-2032, 2004
 
3) 森豊:IGT, 軽症糖尿病に対する介入方法の実際:食事, 運動から薬物療法まで. Prog Med 25:86-92, 2005
Medical*Online
4) Mori Y, Hoshino K, Yokota K et al:Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men. Exp Clin Endocr Diab, 2005 (in press)
 
5) Matsui H, Okumura K, Kawakami K et al:Improved insulin sensitivity by bezafibrate in rats:relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 46:348-353, 1997 (PMID:9032088)
 
6) Inoue I, Takahashi K, Katayama S et al:Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract 25:199-205, 1994 (PMID:7851275)
 
7) 千葉徹, 福田元司, 杉村和彦ほか:インスリン非依存型糖尿病に合併した高脂血症患者におけるベザフィブラートの臨床効果. 臨床医薬 9:1693-1703, 1993
Medical*Online
8) 奥田諭吉, 鈴木誠司, 伊坂正明ほか:インスリン非依存型糖尿病患者の高脂血症および血糖コントロールに及ぼすベザフィブラートの効果. プラクティス 12:75-80, 1995
 
9) 石井英博, 江藤隆, 早木郁人ほか:2型糖尿病患者におけるベザフィブラートの血糖低下作用と脂質代謝改善作用. プラクティス 16:561-566, 1999
 
10) Taniguchi A, Fukushima M, Sakai M et al:Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 50:477-480, 2001 (PMID:11288046)
 
11) Jones IR, Swai A, Taylor R et al:Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM Diabetes Care 13:855-863, 1990 (PMID:2209320)
 
12) Ogawa S, Takeuchi K, Sugimura K et al:Bezafibrate reduced blood glucose in type 2 diabetes mellitus. Metabolism 49:331-334, 2000 (PMID:10726910)
 
13) Tenenbaum A, Motro M, Fisman EZ et al:Peroxisome proliferators-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109:2197-2202, 2004 (PMID:15123532)
 
14) 森豊:糖尿病における動脈硬化進展機序, 高トリグリセリド血症 (高レムナント血症). 循環器医が治療する糖尿病と大血管障害, 代田浩之, 野出孝一編, メディカルビュー, 東京, 2004, pp96-103
 
15) 松浦憲一, 森豊, 疋田美穂ほか:高中性脂肪血症の改善に伴い血清TNF-αが低下, アディポネクチンが上昇し, インスリン抵抗性が改善した2型糖尿病の1例. 糖尿病 46:955-959, 2003
 
16) Mori Y, Komiya H, Kurokawa N et al:Effects of long-term bezafibrate treatment on body fat accumulation and tissue triglyceride content in Otsuka Long-Evans Tokushima Fatty rats:Its relation to the expression of uncoupling Protein 3 mRNA. Jikeikai Med J 50:75-83, 2003
 
17) 小宮秀明, 黒川修行, 森豊ほか:脊柱直立筋内脂肪蓄積と糖負荷試験のインスリン反応との関連性. 肥満研究 5:201-206, 1999
Medical*Online
18) Mori Y, Tokutate Y, Oana F et al:Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues:a study in spontaneously type 2 diabetic rats with visceral obesity. J Atheroscler Thromb 11:224-231, 2004 (PMID:15356383)
 
19) Mori Y, Oana F, Matuszawa A et al:Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues, A study in spontaneously type 2 diabetic rats with visceral obesity. Endocrine 25:247-251, 2004 (PMID:15758252)
 
P.158 掲載の参考文献
1) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001 (PMID:11368702)
 
2) Lakka HM, Laaksonen DE, Lakka TA et al:The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002 (PMID:12460094)
 
3) Matsuzawa Y, Funahashi T, Nakamura T:Molecular mechanism of metabolic syndrome X:contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892:146-154, 1999 (PMID:10842660)
 
4) Unger RH:How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab 8:276-282, 1997
PubMed
5) Unger RH:Lipid overload and overflow:metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 14:398-403, 2003 (PMID:14580758)
 
6) Smith U, Hammersten J, Bjorntorp P et al:Regional differences and effect of weight reduction on human fat cell metabolism Eur Clin Invest 9:327-332, 1979 (PMID:118025)
 
7) McGarry JD, Dobbins RL:Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42:128-138, 1999 (PMID:10064091)
 
8) Kelley DE, Goodpaster BH, Storlien L:Muscle triglyceride and insulin resistance. Annu Rev Nutr 22:325-346, 2002 (PMID:12055349)
 
9) Shulman GI:Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000 (PMID:10903330)
 
10) Ferre P:The biology of peroxisome proliferator-activated receptors:relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (suppl 1):S43-S50, 2004 (PMID:14749265)
 
11) Guerre-Millo M, Gervois P, Raspe E et al:Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000 (PMID:10828060)
 
12) Ye JM, Doyle PJ, Iglesias MA et al:Peroxisome proliferator-activated receptor (PPAR) alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats:comparison with PPAR gamma activation. Diabetes 50:411-417, 2001 (PMID:11272155)
 
13) Zhou YT, Shimabukuro M, Koyama K et al:Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. Proc Natl Acad Sci USA 94:6386-6390, 1997 (PMID:9177227)
 
14) Tenenbaum A, Motro M, Fisman EZ et al:Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109:2197-2202, 2004 (PMID:15123532)
 
P.170 掲載の参考文献
1) Sagawa H, Tazuma S, Kajiyama G:Protection against hydrophobic bile salt-induced cell membrane damage by liposomes and hydrophilic bile salts. Am J Physiol 264 (5pt1):G835-G839, 1993 (PMID:8498510)
 
2) Rosario J, sutherland E, Zaccaro L et al:Ethinylestradiol administration selectively alters liver sinusoidal membrane lipid fluidity and protein composition. Biochemistry 27:3939-3946, 1988 (PMID:3415965)
 
3) Rigotti A, Marzolo MP, Nervi F:Lipid transport from the hepatocyte into bile. Curr Top Membr 40:579-615, 1994
 
4) Smit JJ, Schinkel AH, Oude Elferink RP et al:Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-462, 1993 (PMID:8106172)
 
5) Crawford AR, Smith AJ, Hatch VC et al:Hepatic secretion of phospholipid Vesicles in the Mouse Critically Depends on mdr2 or MDR3 P-Glycoprotein Expression. J Clin Invest 100:2562-2567, 1997 (PMID:9366571)
PubMed
6) Ruetz S, Gros P:Phosphatidylcholine translocase:a physiological role for the mdr2 gene. Cell 77:1071-1081, 1994 (PMID:7912658)
 
7) Lammert F, Wang DQ, Hillebrandt S et al:Spontaneous cholecysto-and hepatolithiasis in Mdr2-/-mice:a model for low phospholipid associated cholelithiasis. Hepatology 39:117-128, 2004 (PMID:14752830)
 
8) de Vree JM, Jacquemin E, sturm E et al:Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 95:282-287, 1998 (PMID:9419367)
 
9) Dixon PH, Weerasekera N, Linton KJ et al:Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy:evidence for a defect in protein trafficking. Hum Mol Genet 9:1209-1217, 2000 (PMID:10767346)
 
10) Rosmorduc O, Hermelin B, Boelle PY et al:ABCB4 gene mutation-associated cholelithiasisin adults. Gastroenterology 125:452-459, 2003 (PMID:12891548)
 
11) Rosmorduc O, Hermelin B, Poupon R:MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120:1459-1467, 2001 (PMID:11313316)
 
12) Gupta S, Todd Stravitz R, Pandak WM et al:Regulation of multidrug resistance 2 P-glyco-protein expression by bile salts in rats and in primary cultures of rat hepatocytes. Hepatology 32:341-347, 2000 (PMID:10915741)
 
13) Chianale J, Vollrath V, Wielandt AM et al:Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 314 781-786, 1996 (PMID:8615769)
 
14) Hooiveld GJ, Vos TA, scheffer GL et al:3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 117:678-687, 1999 (PMID:10464145)
 
15) Wu MK, Boylan MO, Cohen DE:Cloning and gene structure of rat phosphatidylcholine transfer protein, Pctp. Gene 235:111-120, 1999 (PMID:10415339)
 
16) Inoue I, Itoh F, Aoyagi S et al:Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB. Biochem Biophys Res Commun 290:131-139, 2002 (PMID:11779144)
 
17) Tugwood JD, Aldridge Tc, Lambe KG et al:Peroxisome proliferator-activated receptors:structures and function. Ann NY Acad Sci 804:252-265, 1996 (PMID:8993548)
 
18) Palmer CN, Hsu MH, Griffin KJ et al:Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol 53:14-22, 1998 (PMID:9443928)
 
19) Lawrence JW, Li Y Chen S et al:Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α. PPAR α fails to induce peroxisome proliferation-associated genes in:human cells independently of the level of receptor expresson. J Biol Chem 276:31521-31527, 2001 (PMID:11418601)
 
20) Kubitz R, Schmitt M, Horbach A et al:Protein kinase C-dependent distribution of the multi-drug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells. Hepatology 34:340-350, 2001 (PMID:11481619)
 
21) Anwer MS:Cellular regulation of hepatic bile acid transport in health and cholestasis. Hepatology 39:581-590, 2004 (PMID:14999673)
 
22) Kipp H, Arias IM:Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters. Semin Liver Dis 20:339-351, 2000 (PMID:11076400)
 
23) Zegers MM, Hoekstra D:Sphingolipid transport to the apical plasma membrane domain in human hepatoma cells is controlled by PKC and PKA activity:a correlation with cell polarity in HepG2 cells. J Cell Biol 138:307-321, 1997 (PMID:9230073)
 
24) Beuers U, Bilzer M, Chittattu A et al:Taurour-sodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33:1206-1216, 2001 (PMID:11343250)
 
25) Choudhuri BS, Bhakta S, Barik R at al:Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem J 367:279-285, 2002 (PMID:12057006)
 
26) Smith AJ, van Helvoort A, van Meer G et al:MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275:23530-23539, 2000 (PMID:10918072)
 
27) Kok T, Bloks VW,:Wolters H et al:Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 369:539-547, 2003 (PMID:12381268)
 
28) Kok T, Wolters H, Bloks VW et al:Induction of hepatic ABC transporter expression is part ofthe PPARα-mediated fasting response in the mouse. Gastroenterology 124:160-171, 2003 (PMID:12512040)
 
29) Splinter PL, Masyuk AI, LaRusso NF:Specific inhibition of AQP1 water channels in isolated rat intrahepatic bile duct units by small interfering RNAs. J Biol Chem 278:6268-6274, 2003 (PMID:12468529)
 
30) Munshi CB, Graeff R, Lee HC:Evidence for a causal role of CD38 expression in granulocytic differentiation of human HL-60 Cells. J Biol Chem 277:49453-49458, 2002 (PMID:12386160)
 
31) Kano M, Shoda J, Sumazaki R et al:Mutations identified in the human multidrug resistance P-glycoprotein 3 (ABCB4) gene in patients with primary hepatolithiasis. Hepatology Res 29:160-166, 2004 (PMID:15203080)
 
32) Shoda J, Oda K, suzuki H et al:Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi. Hepatology 33:1194-1205, 2001 (PMID:11343249)
 

書評

最近チェックした商品履歴

Loading...